Hepatitis Monthly

Published by: Kowsar

Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial

Hedayat Allah Shahmohammadi 1 , Seyed Ahmad Hosseini 1 , * , Eskandar Hajiani 2 , Amal Saki Malehi 3 and Meysam Alipour 1
Authors Information
1 Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Research Center for Infectious Diseases of the Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Health Research Institute, Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Hepatitis Monthly: April 2017, 17 (4); e12299
  • Published Online: March 26, 2017
  • Article Type: Research Article
  • Received: January 11, 2017
  • Revised: February 19, 2017
  • Accepted: March 8, 2017
  • DOI: 10.5812/hepatmon.45609

To Cite: Shahmohammadi H A, Hosseini S A, Hajiani E, Malehi A S, Alipour M. et al. Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial, Hepat Mon. 2017 ;17(4):e12299. doi: 10.5812/hepatmon.45609.

Abstract
Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6): 1413-9[DOI][PubMed]
  • 2. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, et al. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol. 2014; 20(24): 7718-29[DOI][PubMed]
  • 3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11): 686-90[DOI][PubMed]
  • 4. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12(5): 1106-10[DOI][PubMed]
  • 5. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med (Lond). 2006; 6(1): 19-25[PubMed]
  • 6. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6): 330-44[DOI][PubMed]
  • 7. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010; 52(1): 79-104[DOI][PubMed]
  • 8. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013; 19(29): 5177-92[DOI][PubMed]
  • 9. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2): 372-84[DOI][PubMed]
  • 10. Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017; 83(1): 88-95[DOI][PubMed]
  • 11. Esquivel P, Jiménez VM. Functional properties of coffee and coffee by-products. Food Res Int. 2012; 46(2): 488-95[DOI]
  • 12. van Dam RM. Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer. Appl Physiol Nutr Metab. 2008; 33(6): 1269-83[DOI][PubMed]
  • 13. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007; 22(15): 2242-8[DOI][PubMed]
  • 14. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis. 2009; 16(1): 85-91[DOI][PubMed]
  • 15. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011; 22(3): 503-10[DOI][PubMed]
  • 16. Yesil A, Yilmaz Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013; 38(9): 1038-44[DOI][PubMed]
  • 17. Lecoultre V, Carrel G, Egli L, Binnert C, Boss A, MacMillan EL, et al. Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men. Am J Clin Nutr. 2014; 99(2): 268-75[DOI][PubMed]
  • 18. Gupta V, Mah XJ, Garcia MC, Antonypillai C, van der Poorten D. Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 21(37): 10621-35[DOI][PubMed]
  • 19. Godos J, Pluchinotta FR, Marventano S, Buscemi S, Li Volti G, Galvano F, et al. Coffee components and cardiovascular risk: beneficial and detrimental effects. Int J Food Sci Nutr. 2014; 65(8): 925-36[DOI][PubMed]
  • 20. H VS, K V, Patel D, K S. Biomechanism of chlorogenic acid complex mediated plasma free fatty acid metabolism in rat liver. BMC Complement Altern Med. 2016; 16: 274[DOI][PubMed]
  • 21. Sarriá B, Martínez-López S, Mateos R, Bravo-Clemente L. Long-term consumption of a green/roasted coffee blend positively affects glucose metabolism and insulin resistance in humans. Food Res Int. 2016; 89: 1023-8[DOI]
  • 22. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1): 1-10[DOI][PubMed]
  • 23. Vinson JA, Burnham BR, Nagendran MV. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes. 2012; 5: 21-7[DOI][PubMed]
  • 24. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007; 35(6): 900-8[DOI][PubMed]
  • 25. Health NIO, Obesity Education Initiative NHLBI, Association for the Study of Obesity NA. The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults. 2000;
  • 26. Stohs SJ, Badmaev V. A review of natural stimulant and non-stimulant thermogenic agents. Phytother Res. 2016; 30(5): 732-40[DOI]
  • 27. Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011; 2011[DOI][PubMed]
  • 28. Flanagan J, Bily A, Rolland Y, Roller M. Lipolytic activity of Svetol(R), a decaffeinated green coffee bean extract. Phytother Res. 2014; 28(6): 946-8[DOI][PubMed]
  • 29. Narita Y, Iwai K, Fukunaga T, Nakagiri O. Inhibitory activity of chlorogenic acids in decaffeinated green coffee beans against porcine pancreas lipase and effect of a decaffeinated green coffee bean extract on an emulsion of olive oil. Biosci Biotechnol Biochem. 2012; 76(12): 2329-31[DOI][PubMed]
  • 30. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5(5): 1544-60[DOI][PubMed]
  • 31. Chen Y, Varghese Z, Ruan XZ. The molecular pathogenic role of inflammatory stress in dysregulation of lipid homeostasis and hepatic steatosis. Genes Dis. 2014; 1(1): 106-12[DOI]
  • 32. Yukawa GS, Mune M, Otani H, Tone Y, Liang XM, Iwahashi H, et al. Effects of coffee consumption on oxidative susceptibility of low-density lipoproteins and serum lipid levels in humans. Biochemistry (Mosc). 2004; 69(1): 70-4[DOI][PubMed]
  • 33. Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem. 2002; 13(12): 717-26[DOI][PubMed]
  • 34. Ong KW, Hsu A, Tan BK. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation. Biochem Pharmacol. 2013; 85(9): 1341-51[DOI][PubMed]
  • 35. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008; 28(2): 200-8[DOI][PubMed]
  • 36. Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010; 47(2): 165-9[DOI][PubMed]
  • 37. Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr. 2010; 91(4): 950-7[DOI][PubMed]
  • 38. Ohnaka K, Ikeda M, Maki T, Okada T, Shimazoe T, Adachi M, et al. Effects of 16-week consumption of caffeinated and decaffeinated instant coffee on glucose metabolism in a randomized controlled trial. J Nutr Metab. 2012; 2012: 207426[DOI][PubMed]
  • 39. Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J. 2011; 10: 93[DOI][PubMed]
  • 40. Pham NM, Nanri A, Kochi T, Kuwahara K, Tsuruoka H, Kurotani K, et al. Coffee and green tea consumption is associated with insulin resistance in Japanese adults. Metabolism. 2014; 63(3): 400-8[DOI][PubMed]
  • 41. McAnlis GT, McEneny J, Pearce J, Young IS. Black tea consumption does not protect low density lipoprotein from oxidative modification. Eur J Clin Nutr. 1998; 52(3): 202-6[DOI][PubMed]
  • 42. Mechanisms of disease progression in nonalcoholic fatty liver disease. Seminars in liver disease.
  • 43. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44(6): 1167-74[DOI][PubMed]
  • 44. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22): 2297-307[DOI][PubMed]
  • 45. Maki T, Pham NM, Yoshida D, Yin G, Ohnaka K, Takayanagi R, et al. The relationship of coffee and green tea consumption with high-sensitivity C-reactive protein in Japanese men and women. Clin Chem Lab Med. 2010; 48(6): 849-54[DOI][PubMed]
  • 46. Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010; 52(5): 1652-61[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments